Breaking News
2 days ago
Simantini Singh Deo
Ocugen gets FDA nod for Phase 2/3 trial of OCU410ST gene therapy for Stargardt disease.
Vaibhavi M.
Centessa gets FDA clearance to begin Phase 1 trial of ORX142, a novel OX2R agonist for neurological conditions.
Simantini Singh Deo
Hepion appoints Dr. Kaouthar Lbiati as interim CEO, signaling a strategic pivot in precision diagnostics.
Simantini Singh Deo
Osmol wins EU patent for OSM-0205, advancing protection against chemo-induced neuropathy and cognitive impairment.
Simantini Singh Deo